Выбор блокатора ангиотензиновых рецепторов на разных этапах сердечнососудистого континуума

В статье представлены современные представления о компонентах, физиологических и патофизиологических эффектах ренин-ангиотензин-альдостероновой системы, путях ее гиперактивации на различных этапах сердечно-сосудистого и почечного континуума. Особое внимание уделено блокаторам рецепторов ангиотензина (сартанам). Приведены результаты многоцентровых рандомизированных клинических исследований, проведенных с препаратами данной группы. На основе их анализа определены клинические ситуации, позволяющие врачу сделать выбор в пользу того или иного препарата. Так, предпочтительным для пациентов с множественными факторами риска развития сердечно-сосудистых осложнений является назначение телмисартана, при нефропатии - ирбесартана, перенесшим острый инфаркт миокарда - валсартана, а при клинических признаках хронической сердечной недостаточности с низкой фракцией выброса - лозартана, валсартана и кандесартана.

сердечно-сосудистый континуум, блокаторы ангиотензиновых рецепторов, cardiovascular continuum, angiotensin receptor blockers

1. Рекомендации ВНОК по диагностике и лечению артериальной гипертензии 2001. Consilium medicum. Приложение: Артериальная гипертония 2001;1 (3):3-16.

2. McMurray J. ACE-inhibitors in cardiovascular disease - unbeatable? N. Eng J. Med 2008;358:1615-1616.

3. Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр). Системные гипертензии 2010;3:5-25

4. Национальные рекомендации: Сердечно-сосудистый риск и хроническая болезнь почек: стратегии кардио-нефропротекции. Российский кардиологический журнал 2014;8:7-37

5. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2016;37:2129-2200

6. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2013;34:3035-3087.

7. Dzau V., Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 1991;121 (4 Pt 1):1244-1263.

8. Wagner M., Tiffe T., Morbach C., еt al. STAAB-Consortium. Characteristics and Course of Heart Failure Stages A - B and Determinants of Progression - design and rationale of the STAAB cohort study. Eur J Prev Cardiol 2017;24 (5):468-479. https://doi.org/10.1177/2047487316680693

9. O'Rourke M. F., Safar M. E., Dzau V. The Cardiovascular Continuum extended: aging effects on the aorta and microvasculature. Vasc Med. 2010;15 (6):461-468. https://doi.org/10.1177/1358863X10382946

10. Kim S. A., Park J. B., O'Rourkе М. F. Vasculopathy of aging and the revised cardiovascular continuum. Pulse (Basel) 2015;3 (2):141-147. https://doi.org/10.1159/000435901

11. Morgan L., Broughton P. F., Kalsheker N. Angiotensinogen: molecular biology, biochemistry and physiology. Int J. Biochem Cell Biol 1996;28:1211-1222.

12. Ahmad S., Varagic J., Groban L., Dell'Italia L.J. et al. Angiotensin-(1-12): a chymase-mediated cellular angiotensin II substrate Curr Hypertens Rep 2014;16 (5):429. https://doi.org/10.1007/s11906-014-0429-9

13. Ferrario C. M. Cardiac remodelling and ^AS inhibition. Ther Adv Cardiovasc Dis 2016;10 (3):162-171. https://doi.org/10.1177/1753944716642677.

14. Liao Y., Husain A. The chymase-angiotensin system in humans: biochemistry, molecular biology and potential role in cardiovascular diseases. Can J. Cardiol 1995;11 Suppl F:13F - 19F.

15. Dell'Italia L. J., Ferrario C. M. The never-ending story of angiotensin peptides: beyond angiotensin I. and I.I. Circ Res 2013;112 (8):1086-1087. https://doi.org/10.1161/CIRCRESAHA.113.301246.

16. Zhang H., Han G. W., Batyuk A., Ishchenko A. et al. Structural basis for selectivity and diversity in angiotensin II receptors. Nature 2017; 544 (7650):327-332. https://doi.org/10.1038/nature22035.

17. Tadevosyan A., Xiao J., Surinkaew S., Naud P. et al. Intracellular angiotensin-II interacts with nuclear angiotensin receptors in cardiac fibroblasts and regulates RNA synthesis, cell proliferation, and collagen secretion. J. Am Heart Assoc 2017;6 (4):e004965. https://doi.org/10.1161/JAHA.116.004965

18. Sugawara A., Takeuchi K., Uruno A., Ikeda Y. et al. Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-gamma in vascular smooth muscle cells. Endocrinology 2001;142 (7):3125-3134

19. de Kloet A. D., Steckelings U. M., Sumners C. Protective Angiotensin Type 2 Receptors in the Brain and Hypertension. Curr Hypertens Rep 2017;19 (6):46. https://doi.org/10.1007/s11906-017-0746-x

20. Pharmacologic group - angiotensin II receptor antagonists. (Фармакологическая группа - Антагонисты рецепторов ангиотензина II (An-подтип)) http://www.rlsnet.ru/fg_index_ id_187.htm. (20.06.2017)

21. Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. AmJ Cardiol 2002;89 (2A): 3A - 10A

22. Hass A., Oz H., Mashavi M., Shargorodsky M. Role of RAAS and adipokines in cardiovascular protection: effect of different doses of angiotensin II receptor blocker on adipokines level in hypertensive patients. J Am Soc Hypertens 2014;8 (10):709-714. https://doi.org/10.1016/j.jash.2014.07.033

23. James P. A., Oparil S., Carter B. L. et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) JAMA 2014;311 (5):507-520. https://doi.org/10.1001/jama.2013.284427

24. Weber M. A., Schiffrin E. L., White W. B., Mann S. et al. Clinical Practice Guidelines for the Management of Hypertension in the Community A Statement by the American Society of Hypertension and the International Society of Hypertension. http://www.ash-us.org/documents/JCH_HTN_ Guidelines_2013.pdf (18.06.2017)

25. Dahlot B., Devereux R. D., Kjeldsen S. E. et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.

26. Julius S., Kjeldsen S. E., Weber M. et al., VALUE trial group. Outcomes inhypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-2031.

27. Ogihara T., Saruta T., Matsuoka H. et al. Valsartan in elderly isolated systolic hypertension (VALISH) study: rationale and design. Hypertens Res 2004;27 (9):657-661.

28. Lithell H., Hansson L., Elmfeldt D. et al. The Study of Cognition and Prognosis in the Elderly (SCOPE). J. Hypertens 2003;21:875-886.

29. Yusuf S., Teo K., Anderson C., Pogue J. et al. The TRANSCEND investigators. Effects of the angiotensin-receptor blocker telmis-artan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008;372:1174-1183. https://doi.org/10.1016/S0140-6736 (08) 61242-8.

30. Williams B., Lacourcière Y., Schumacher H., Gosse P. et al. Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I. and II randomized trials. J. Hum Hypertens 2009;23 (9):610-619. https://doi.org/10.1038/jhh.2009.4.

31. Гуревич М. А., Кузьменко Н. А. Использование сартанов в кардиологической практике. РМЖ 2017;4:265-268

32. Verdecchia P., Angeli F., Repaci S. et al. Comparative assessment of angiotensin receptor blockers in different clinical settings Vasc Health Risk Manag 2009;5:939-948.

33. Cuspidi C., Muiesan M. L., Valagussa L. et al. CATCH investigators Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J. Hypertens 2002;20 (11):2293-300.

34. Подзолков В. И., Тарзиманова А. И. Телмисартан в лечении гипертензивных пациентов. Терапевтический архив 2017;89 (6):110-113

35. Lacourcière Y., Krzesinski J. M., White W. B., at al. Sustained antihypertensive activity of telmisartan compared with valsartan. Blood Press Monit 2004;9 (4):203-210.

36. Национальные рекомендации по диагностике и лечению острого инфаркта миокарда (ОИМ) с повышением сегмента ST на ЭКГ. Кардиоваскулярная терапия и профилактика 2007;6 (8):Приложение 1.

37. Velazquez E.J., Pfeffer M. A., Mc Murray J. V. et al. Valsartan In Acute myocardial Infarction (VALIANT) trial: baseline characteristics in context. Eur J. Heart Fail 2003;5:537-44.

38. The ONTARGET investigators. Telmisartan, ramipril or both in patients at high risk for vascular events. N. Engl J. Med 2008;358:1547-1559.

39. Yusuf S., Sleight P., Pogue J. et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl J. Med 2000;342:145-153.

40. Abdul-Rahim A. H., Perez A. C., MacIsaac R. L., Jhund P. S. et al. Candesartan in Heart failure Assessment of Reduction in Mortality and Morbidity-Preserved (CHARM-Preserved) and the Irbesartan in Heart Failure with Preserved Systolic Function (I-Preserve) Steering Committees. Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials. Eur Heart J. 2017;38 (10):742-750. https://doi.org/10.1093/eurheartj/ehw50.

41. Verdecchia P., Dagenais G., Healey J. et al.; Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease Investigators. Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease studies. J. Hypertens 2012;30 (5):1004-1014. https://doi.org/10.1097/HJH.0b013e3283522a51

42. Florea V. G., Rector T. S., Anand I. S., Cohn J. N. Heart failure with improved ejection fraction: clinical characteristics, correlates of recovery, and survival: results from the valsartan heart failure trial. Circ Heart Fail 2016;9 (7):pii: e003123. https://doi.org/10.1161/ CIRCHEARTFAILURE.116.003123

43. Konstam M. A., Neaton J. D., Poole-Wilson P. A. et al. ELITE II Investigators Comparison of losartan and captopril on heart failure-related outcomes and symptoms from the losartan heart failure survival study (ELITE II). Am Heart J. 2005;150 (1):123-131.

44. Starling R. C., Estep J. D., Horstmanshof D. A. et al. ROADMAP Study Investigators. Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients: The ROADMAP Study 2-Year Results. JACC Heart Fail 2017; pii: S2213-1779 (17):518-527. https://doi.org/10.1016/j.jchf.2017.02.016

45. Sharma A. M., Hollander A., Koster J.; on behalf of the Efficacy and Safety in Patients with Renal Impairment treated with Telmisartan (ESPRIT) Study Group. Telmisartan in patients with mild/moderate hypertension and chronic kidney disease. Clin Nephrol 2005;63 (4):250-257.

46. Hellemons M. E., Persson F., Bakker S. J. et al. Initial angiotensin receptor blockade-induced decrease in albuminuria is associated with long-term renal outcome in type 2 diabetic patients with microalbuminuria: a post hoc analysis of the IRMA-2 trial. Diabetes Care 2011;34 (9):2078-2083. https://doi.org/10.2337/dc11-0324

47. Riphagen I.J., Deetman P. E., Bakker S.J. et al. Bilirubin and progression of nephropathy in type 2 diabetes: a post hoc analysis of RENAAL with independent replication in IDNT. Diabetes 2014;63 (8):2845-2853. https://doi.org/10.2337/db13-1652

48. Viberti G., Wheeldon N. M.; MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators/Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106 (6):672-678.

49. Galle J., Schwedhelm E., Pinnetti S. et al. VIVALDI investigators Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transplant 2008;23 (10):3174-3183. https://doi.org/10.1093/ndt/gfn230.

50. Bakris G., Burgess E., Weir M. et al.; on behalf of the AMADEO Study Investigators. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int 2008;74 (3):364. https://doi.org/10.1038/ki.2008.204.